Novavax (NVAX) Current Assets (2010 - 2026)
Novavax (NVAX) posted quarterly Current Assets of $850.8 million for Q1 2026, down 1.98% year-over-year from $868.0 million in Q1 2025, and down 13.03% quarter-over-quarter from $978.3 million in Q4 2025.
Novavax (NVAX) Current Assets (2010 - 2026) Analysis & Trends
Novavax's Current Assets history runs 17 years deep, the most recent figure standing at $850.8 million for Q1 2026.
- In Q1 2026, Current Assets fell 1.98% year-over-year to $850.8 million; the TTM figure through Mar 2026 stood at $850.8 million (down 1.98% YoY), while the FY2025 annual figure was $978.3 million, down 13.35% from the prior year.
- Current Assets for Q1 2026 stood at $850.8 million, down from $978.3 million in the prior quarter.
- The five-year high for Current Assets was $2.3 billion in Q1 2022, with the low at $727.1 million in Q1 2024.
- The 5-year median for Current Assets is $1.1 billion (2024), against an average of $1.2 billion.
- The sharpest annual moves came in 2023 and 2025: Current Assets sank 58.63% in 2023, then increased 19.38% in 2025.
- Novavax's Current Assets stood at $1.7 billion in 2022, then plunged by 32.85% to $1.1 billion in 2023, then slipped by 1.31% to $1.1 billion in 2024, then slipped by 13.35% to $978.3 million in 2025, then retreated by 13.03% to $850.8 million in 2026.
- Business Quant data shows NVAX's Current Assets at $850.8 million in Q1 2026, $978.3 million in Q4 2025, and $974.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 771.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 771.10 Mn |
| Mar 31, 2026 | 850.82 Mn |
| Dec 31, 2025 | 978.28 Mn |
| Sep 30, 2025 | 974.59 Mn |
| Jun 30, 2025 | 919.51 Mn |
| Mar 31, 2025 | 868.03 Mn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 1.10 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Mar 31, 2024 | 727.12 Mn |
| Dec 31, 2023 | 1.14 Bn |
| Sep 30, 2023 | 1.01 Bn |
| Jun 30, 2023 | 1.13 Bn |
| Mar 31, 2023 | 971.03 Mn |
| Dec 31, 2022 | 1.70 Bn |
| Sep 30, 2022 | 1.76 Bn |
| Jun 30, 2022 | 2.14 Bn |
| Mar 31, 2022 | 2.35 Bn |
| Dec 31, 2021 | 2.16 Bn |
| Sep 30, 2021 | 2.17 Bn |